Review maps peptide-drug conjugate design against antibody-drug conjugates

The wire

1. 01The review covers tumor-homing peptide ligands against integrins and GPCRs, enzyme-sensitive, redox-responsive and pH-cleavable linkers, and theranostic conjugates carrying imaging moieties or radiolabels.
2. 02Peptide-drug conjugates are a growing slice of the approved and pipeline peptide-therapeutic landscape that readers tracking oncology peptides will encounter.
3. 03The authors list rapid renal clearance, proteolytic degradation and short circulation half-life as unresolved, with cyclization, PEGylation and albumin binding proposed but not settled; this is a narrative review, not new data.

From the source

Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges

Advanced drug delivery reviews · 2026 Aug 31 · Kumar A, Sharma R, Yadav AK et al.